Literature DB >> 15892451

Translational downregulation of the noncatalytic growth factor receptor TrkB.T1 by ischemic preconditioning of primary neurons.

Julius A Steinbeck1, Axel Methner.   

Abstract

Short episodes of ischemia can protect neuronal cells and tissue against a subsequent lethal ischemia by a phenomenon called ischemic preconditioning. The development of this tolerance depends on protein synthesis and takes at least 1 day. It therefore seems reasonable that preconditioning leads to upregulation and translation of protective genes or posttranslational modification of pro- or antiapoptotic proteins. We recently used suppression subtractive hybridization to identify transcripts upregulated in rat primary neuronal cultures preconditioned by oxygen glucose deprivation. In this contribution, we describe the previously unknown 7-kb full-length sequence of an upregulated expressed sequence tag and show that it constitutes the 3' end of the large untranslated region of the noncatalytic "truncated" growth factor receptor TrkB.T1. TrkB.T1 is expressed most prominently in the adult brain and its mRNA was found to be 2.1-fold upregulated by ischemic preconditioning. At the protein level, however, TrkB.T1 was clearly downregulated, possibly by increased degradation in preconditioned cultures. TrKB.T1 can act as a dominant-negative inhibitor of its catalytic counterpart TrkB, which is the receptor for brain-derived neurotrophic factor (BDNF), a factor induced by ischemia that can protect from ischemia-induced neuron loss. We hypothesize that the downregulation of TrkB.T1 at the protein level can prolong BDNF-mediated protective signaling via the catalytic receptor and thus participates in the development of ischemic preconditioning.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15892451      PMCID: PMC6009108          DOI: 10.3727/000000005783992142

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  38 in total

1.  Induced tolerance to ischemia in gerbil hippocampal neurons.

Authors:  T Kirino; Y Tsujita; A Tamura
Journal:  J Cereb Blood Flow Metab       Date:  1991-03       Impact factor: 6.200

2.  Brain-derived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat.

Authors:  I Ferrer; J Krupinski; E Goutan; E Martí; S Ambrosio; E Arenas
Journal:  Acta Neuropathol       Date:  2001-03       Impact factor: 17.088

3.  K+ channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid beta-protein precursor genes and neuronal death in rat hippocampus.

Authors:  C Heurteaux; V Bertaina; C Widmann; M Lazdunski
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

4.  Staurosporine, a novel protein kinase C inhibitor, prevents postischemic neuronal damage in the gerbil and rat.

Authors:  H Hara; H Onodera; M Yoshidomi; Y Matsuda; K Kogure
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

5.  The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning.

Authors:  R Bolli; S Manchikalapudi; X L Tang; H Takano; Y Qiu; Y Guo; Q Zhang; A K Jadoon
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

6.  BDNF up-regulates TrkB protein and prevents the death of CA1 neurons following transient forebrain ischemia.

Authors:  I Ferrer; J Ballabriga; E Martí; E Pérez; J Alberch; E Arenas
Journal:  Brain Pathol       Date:  1998-04       Impact factor: 6.508

7.  Neurotoxic injury in rat hippocampus differentially affects multiple trkB and trkC transcripts.

Authors:  N Belluardo; T Salin; P Dell'Albani; G Mudò; M Corsaro; X H Jiang; T Timmusk; D F Condorelli
Journal:  Neurosci Lett       Date:  1995-08-18       Impact factor: 3.046

8.  Brain-derived neurotrophic factor protects against ischemic cell damage in rat hippocampus.

Authors:  T Beck; D Lindholm; E Castrén; A Wree
Journal:  J Cereb Blood Flow Metab       Date:  1994-07       Impact factor: 6.200

9.  Tyrosine phosphorylation and activation of mitogen-activated protein kinase in the rat brain following transient cerebral ischemia.

Authors:  B R Hu; T Wieloch
Journal:  J Neurochem       Date:  1994-04       Impact factor: 5.372

10.  Neither moderate hypoxia nor mild hypoglycaemia alone causes any significant increase in cerebral [Ca2+]i: only a combination of the two insults has this effect. A 31P and 19F NMR study.

Authors:  R S Badar-Goffer; N M Thatcher; P G Morris; H S Bachelard
Journal:  J Neurochem       Date:  1993-12       Impact factor: 5.372

View more
  5 in total

1.  Nucleotide sequence variation within the human tyrosine kinase B neurotrophin receptor gene: association with antisocial alcohol dependence.

Authors:  K Xu; T R Anderson; K M Neyer; N Lamparella; G Jenkins; Z Zhou; Q Yuan; M Virkkunen; R H Lipsky
Journal:  Pharmacogenomics J       Date:  2007-01-02       Impact factor: 3.550

Review 2.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

Review 3.  Molecular and genetic substrates linking stress and addiction.

Authors:  Lisa A Briand; Julie A Blendy
Journal:  Brain Res       Date:  2009-11-10       Impact factor: 3.252

4.  Expression of full-length and truncated trkB in human striatum and substantia nigra neurons: implications for Parkinson's disease.

Authors:  Mark E Fenner; Cristian L Achim; Barbara Murray Fenner
Journal:  J Mol Histol       Date:  2013-12-29       Impact factor: 2.611

Review 5.  Function and Mechanisms of Truncated BDNF Receptor TrkB.T1 in Neuropathic Pain.

Authors:  Tuoxin Cao; Jessica J Matyas; Cynthia L Renn; Alan I Faden; Susan G Dorsey; Junfang Wu
Journal:  Cells       Date:  2020-05-11       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.